Phase I

Phase I Safety Review — NTX-101

Safety, tolerability, laboratory, and vital-sign review for NTX-101 early development assessment.

Integrated report Program overview Data lineage Model review Phase I Phase II Phase III

Gate Decision: GO

Key safety metrics

MetricValue
AE rate difference vs placebo (pp)13.82
Any AE p-value0.0057
Active any-AE rate (%)92.86
Placebo any-AE rate (%)80.23
Serious AE rate difference vs placebo (pp)2.38
Serious AE p-value0.553
Active serious-AE rate (%)1.79
Placebo serious-AE rate (%)0.0
Critical lab clusterFalse
Treatment-related death imbalanceFalse

Population summary

TreatmentSubjectsMean age
ntx101_high8474.38
ntx101_low8475.67
placebo8675.21

AE incidence

TreatmentN subjectsSubjects with AEAE rate (%)
ntx101_high 84 79 94.05
ntx101_low 84 77 91.67
placebo 86 69 80.23

Statistical checks

ComparisonStatisticp-value
Age balance active vs placebo-0.16610.8683
Any AE rate active vs placebo13.820.0057
Serious AE rate active vs placebo2.3810.553

Figures

AE incidence
lab mean change
vitals mean change
Disclaimer: This review includes analyses derived from a combination of publicly available structural source data and documented synthetic continuity extensions for the fictional NTX-101 program. It is intended for internal methodological demonstration only and is not intended for external publication, regulatory submission, or treatment decision-making.